Abstract

Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.

Keywords

MedicineCoronavirus disease 2019 (COVID-19)ImmunosuppressionPandemicDiseaseAngiotensin-converting enzyme 2Angiotensin-converting enzymeSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronavirusAngiotensin Receptor BlockersIntensive care medicineInternal medicineImmunologyInfectious disease (medical specialty)Blood pressure

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
review
Volume
141
Issue
20
Pages
1648-1655
Citations
1750
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1750
OpenAlex

Cite This

Kevin J. Clerkin, J. Fried, J. Raikhelkar et al. (2020). COVID-19 and Cardiovascular Disease. Circulation , 141 (20) , 1648-1655. https://doi.org/10.1161/circulationaha.120.046941

Identifiers

DOI
10.1161/circulationaha.120.046941